Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
| ▸ | FLT4 | P35916 | 2/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2968326 | 0.80 | AKT1 (0.39) | KDRCYP2A6 | |
| SCHEMBL4789877 | 0.77 | IKBKB (0.47) | KDRFLT1FLT4CYP2A6CYP2B6 | |
| SCHEMBL2974547 | 0.74 | KDR (0.34) | KDRFLT1FLT4CYP2A6CYP2B6 | |
| SCHEMBL2972065 | 0.73 | PDE10A (0.40) | CYP2A6CYP2B6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1290194 | 0.71 | PDE10A (0.42) | — | |
| SCHEMBL15690266 | 0.67 | PDE10A (0.35) | CYP2C9 | |
| SCHEMBL15690188 | 0.67 | PDE10A (0.35) | — | |
| SCHEMBL9953926 | 0.66 | CYP2A6 (0.50) | CYP2A6CYP2B6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5468136 | 0.65 | PDE10A (0.53) | CYP2A6PIK3CGFYNARADORA2A | |
| SCHEMBL11157418 | 0.64 | KDR (0.42) | KDRFLT1FLT4CYP2A6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396330-B1 | FUSED PYRIMIDINES | BAYER IP GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-8957064-B2 | Fused pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (US) | 2015-02-17 | — | — | US | disclosed |
| US-8614218-B2 | Fused bicyclic pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-24 | — | — | US | disclosed |
| US-20130317002-A1 | FUSED PYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-28 | — | — | US | disclosed |
| EP-2188291-B1 | FUSED BICYCLIC PYRIMIDINES | Bayer Pharma AG (DE) | 2012-09-19 | — | — | EP | disclosed |
| EP-2396330-A1 | FUSED PYRIMIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010091808-A1 | FUSED PYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | WO | disclosed |
| US-7776864-B2 | Fused bicyclic pyrimidines | BAYER SCHERING PHARMA AG (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20100184782-A1 | FUSED BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20090137607-A1 | FUSED BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137607-A1 | FUSED BICYCLIC PYRIMIDINES | PIK3CA, TYMS, MTOR | KDR 263/4885FLT1 413/4885FLT4 390/4885 |
| US-20130317002-A1 | FUSED PYRIMIDINES | PIK3CA, MTOR, TYMS | KDR 390/4885FLT1 439/4885FLT4 516/4885 |
| US-20100184782-A1 | FUSED BICYCLIC PYRIMIDINES | PIK3CA, TYMS, MTOR | KDR 263/4885FLT1 413/4885FLT4 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.